Lord Abbett & CO. LLC Sells 68,531 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Lord Abbett & CO. LLC trimmed its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 24.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 215,628 shares of the company's stock after selling 68,531 shares during the period. Lord Abbett & CO. LLC owned about 0.75% of Krystal Biotech worth $33,780,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Krystal Biotech in the fourth quarter worth approximately $34,391,000. Raymond James Financial Inc. bought a new stake in Krystal Biotech in the fourth quarter worth approximately $15,989,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after purchasing an additional 71,200 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock valued at $43,774,000 after purchasing an additional 62,178 shares during the last quarter. Finally, TimesSquare Capital Management LLC boosted its holdings in Krystal Biotech by 39.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock worth $24,888,000 after purchasing an additional 44,646 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

KRYS has been the subject of a number of recent research reports. Citigroup upped their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. HC Wainwright upped their price objective on shares of Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a report on Monday. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, Chardan Capital upped their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $222.71.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS traded up $1.67 during mid-day trading on Monday, hitting $169.73. The company had a trading volume of 167,657 shares, compared to its average volume of 295,598. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34. The firm has a market cap of $4.90 billion, a P/E ratio of 56.77 and a beta of 0.75. The business's 50-day simple moving average is $176.24 and its 200-day simple moving average is $171.50.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. During the same period in the prior year, the firm posted $0.30 EPS. Krystal Biotech's quarterly revenue was up 116.4% compared to the same quarter last year. As a group, sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).